GB201103762D0 - Means and methods for the treatment of neurodegenerative disorders - Google Patents

Means and methods for the treatment of neurodegenerative disorders

Info

Publication number
GB201103762D0
GB201103762D0 GB201103762A GB201103762A GB201103762D0 GB 201103762 D0 GB201103762 D0 GB 201103762D0 GB 201103762 A GB201103762 A GB 201103762A GB 201103762 A GB201103762 A GB 201103762A GB 201103762 D0 GB201103762 D0 GB 201103762D0
Authority
GB
United Kingdom
Prior art keywords
treatment
methods
disease
directed against
neurodegenerative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201103762A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Life Sciences Research Partners vzw
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Life Sciences Research Partners vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB, Life Sciences Research Partners vzw filed Critical Vlaams Instituut voor Biotechnologie VIB
Priority to GB201103762A priority Critical patent/GB201103762D0/en
Publication of GB201103762D0 publication Critical patent/GB201103762D0/en
Priority to PCT/EP2012/053646 priority patent/WO2012119949A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

The present invention has found that inhibitors reducing the glycolytic flux can be used for treatment of neurodegenerative diseases such as Alzheimer's disease, Parkonson's disease and amyotrophic lateral sclerosis. In particular the invention provides constructs comprising siRNAs directed against PHD1 for the treatment of ALS and siRNA's directed against PFKFB3 for the treatment of neurodegenerative diseases. The invention also provides the use of a therapeutically effective amount of aza chalcones or a pharmaceutically acceptable salt thereof for the treatment of neurological diseases.
GB201103762A 2011-03-04 2011-03-07 Means and methods for the treatment of neurodegenerative disorders Ceased GB201103762D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201103762A GB201103762D0 (en) 2011-03-07 2011-03-07 Means and methods for the treatment of neurodegenerative disorders
PCT/EP2012/053646 WO2012119949A1 (en) 2011-03-04 2012-03-02 Means and methods for the treatment of neurodegenerative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201103762A GB201103762D0 (en) 2011-03-07 2011-03-07 Means and methods for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
GB201103762D0 true GB201103762D0 (en) 2011-04-20

Family

ID=43923244

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201103762A Ceased GB201103762D0 (en) 2011-03-04 2011-03-07 Means and methods for the treatment of neurodegenerative disorders

Country Status (2)

Country Link
GB (1) GB201103762D0 (en)
WO (1) WO2012119949A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187934A1 (en) * 2014-06-06 2015-12-10 Cureveda, Llc Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use
CN113396145A (en) * 2018-10-15 2021-09-14 盖罗发现有限责任公司 PFKFB3 inhibitors and uses thereof
CA3218941A1 (en) * 2021-05-16 2022-11-24 Slavica TUDZAROVA-TRAJKOVSKA Methods and compositions for treating neurological conditions
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
WO2005014815A1 (en) * 2003-08-08 2005-02-17 President And Fellows Of Harvard College siRNA BASED METHODS FOR TREATING ALZHEIMER’S DISEASE
JP2010531304A (en) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド PFKFB3 inhibitor family with antineoplastic activity

Also Published As

Publication number Publication date
WO2012119949A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
SG194701A1 (en) Anti-cd40 antibodies and methods of use
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
PH12015500879A1 (en) Compositions and methods for treating proteinopathies
WO2013061161A3 (en) New combination therapies for treating neurological disorders
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MY161656A (en) Therapeutic use of diaminophenothiazines
EA201891833A1 (en) COMBINATION FOR THE TREATMENT OF AMIOTROPHIC SIDE SCLEROSIS OR RELATED DISEASES
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX348941B (en) Means and methods for treating and/or preventing natural ahr ligand-dependent cancer.
MX2009010407A (en) Fluorinated derivatives of deferiprone.
IN2015DN00450A (en)
PH12015500664A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
MX2019001977A (en) Methods and compositions for treating multiple sclerosis and related disorders.
MX349224B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease.
PH12014501140A1 (en) Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
MX2014001766A (en) Neuregulin antibodies and uses thereof.
GB201103762D0 (en) Means and methods for the treatment of neurodegenerative disorders
MX340536B (en) Egfr targeted therapy.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)